DrugPatentWatch Database Preview
Drugs in Development Information for Mibefradil
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Mibefradil?
Mibefradil is an investigational drug.
There have been 5 clinical trials for Mibefradil.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 28th 2018.
The most common disease conditions in clinical trials are Central Nervous System Neoplasms, Dyslipidemias, and Glioblastoma. The leading clinical trial sponsors are Cavion LLC, Ankara University, and LifeWatch Services, Inc.
There are nine hundred and eighty-four US patents protecting this investigational drug and eight international patents.
Summary for Mibefradil
| US Patents | 984 |
| International Patents | 8,058 |
| US Patent Applications | 1,838 |
| WIPO Patent Applications | 1,144 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2018-05-28) |
| Vendors | 28 |
Recent Clinical Trials for Mibefradil
| Title | Sponsor | Phase |
|---|---|---|
| Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population | Instituto Nacional de Salud Publica, Mexico | Phase 3 |
| Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population | Laboratorios Grossman, S.A. | Phase 3 |
| TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM | Yale University | Phase 1 |
Clinical Trial Summary for Mibefradil
Top disease conditions for Mibefradil
Top clinical trial sponsors for Mibefradil
US Patents for Mibefradil
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Mibefradil | Start Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | Start Trial |
| Mibefradil | Start Trial | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | Start Trial |
| Mibefradil | Start Trial | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (Basel, CH) | Start Trial |
| Mibefradil | Start Trial | Ultra-pure agonists of guanylate cyclase C, method of making and using same | SYNERGY PHARMACEUTICALS, INC. (New York, NY) | Start Trial |
| Mibefradil | Start Trial | Liquid dosage forms of sodium naproxen | Patheon Softgels, Inc. (High Point, NC) | Start Trial |
| Mibefradil | Start Trial | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder | Axovant Sciences GmbH (Basel, CH) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Mibefradil
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Mibefradil | European Patent Office | 2981556 | 2033-04-02 | Start Trial |
| Mibefradil | World Intellectual Property Organization (WIPO) | 2014165513 | 2033-04-02 | Start Trial |
| Mibefradil | Australia | 2015210983 | 2034-01-30 | Start Trial |
| Mibefradil | Canada | 2934936 | 2034-01-30 | Start Trial |
| Mibefradil | China | 105992763 | 2034-01-30 | Start Trial |
| Mibefradil | European Patent Office | 3099678 | 2034-01-30 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
